Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
Cleemput
Irina
I
Thiry
Nancy
N
D001530:Belgium; D002648:Child; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D008390:Markov Chains; D018803:Models, Economic; D030361:Papillomavirus Infections / Q000150:complications / Q000191:economics* / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000191:economics* / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D002578:Uterine Cervical Dysplasia / Q000150:complications
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines